$-0.91 EPS Expected for UroGen Pharma Ltd. (URGN)

July 14, 2018 - By Ash Ash

Analysts expect UroGen Pharma Ltd. (NASDAQ:URGN) to report $-0.91 EPS on August, 13.They anticipate $0.21 EPS change or 30.00 % from last quarter’s $-0.7 EPS. After having $-0.88 EPS previously, UroGen Pharma Ltd.’s analysts see 3.41 % EPS growth. The stock decreased 2.67% or $1.31 during the last trading session, reaching $47.73. About 72,161 shares traded. UroGen Pharma Ltd. (NASDAQ:URGN) has risen 228.14% since July 14, 2017 and is uptrending. It has outperformed by 215.57% the S&P500.

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. The company has market cap of $738.57 million. The Company’s lead product candidates, MitoGel and VesiGel are formulations of the chemotherapy drug Mitomycin C, a generic drug which is currently used off-label for urothelial cancer treatment only in a water formulation as an adjuvant, or supplemental post-surgery, therapy. It currently has negative earnings. The firm is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer.

More important recent UroGen Pharma Ltd. (NASDAQ:URGN) news were published by: Multichannel.com which released: “Qwilt Appoints Yoni Mizrahi as Chief Financial Officer” on June 21, 2018, also Streetinsider.com published article titled: “UroGen Pharma (URGN) Submits IND Application for UGN-102 for Treatment of Low-Grade Non-Muscle Invasive …”, Streetinsider.com published: “UroGen Pharma (URGN) Names Shawn Cline Tomasello to Board” on July 10, 2018. More interesting news about UroGen Pharma Ltd. (NASDAQ:URGN) was released by: Nasdaq.com and their article: “UroGen Pharma Appoints Shawn Cline Tomasello to its Board of Directors” with publication date: July 10, 2018.

UroGen Pharma Ltd. (NASDAQ:URGN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: